The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (9 analysts) rates it none, with a mean price target of $56. It reported earnings in this window, a natural checkpoint for the thesis.
Sanofi SA SNY
Clears both ethical standards
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
read at $43.35
Sanofi SA holds its Markup at $43.35.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 181 days |
| Price | $43.35 |
| Valuation | 19.18 trailing · 8.43 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.28 |
The opportunity · what the numbers say it is worth
Our framework reads OPPORTUNITY — it trades at roughly a 45% discount to our $63.00 fair value, 6.00% revenue growth.
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
| Revenue growth | 6.00% |
| Profit margin | 15.95% |
| Debt to equity | 27.37 |
| Analyst consensus | Buy · 9 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✓ PASSES
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is just 16.0% of its assets, well under the one-third ceiling — it does not run on borrowed money. Pass
- Interest-bearing cash Cash held in interest-bearing accounts and securities is 6.0% of assets, under the one-third limit. Pass
- Receivables Money owed to the company is 0.6% of assets, under the 49% limit. Pass
- Revenue purity Only 0.3% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Everyday jabs that still need funding
When a toddler gets their Hib vaccine or a family in Toulouse starts treatment for a rare disease, Sanofi is often the quiet supplier behind it. The shares sit at 8.7 times forward earnings with 6 percent revenue growth and a 16 percent profit margin, yet the market prices the business well below our fair value. It clears our ethical screen without flags, and nine analysts still cluster around a lower target than the numbers support.
The 41 percent margin of safety comes from steady demand for vaccines and specialist medicines that do not vanish in a downturn. ROE at 7 percent is modest, but the cash flow profile looks durable for a business this size and the opportunity rating reflects exactly that gap between price and value.
Patent cliffs, pricing pressure from governments, and unknown competitive edges remain real risks in any large drug maker. Currency moves and regulatory shifts in Europe can also bite harder than expected. Analysis, not advice.
| Forward P/E | 8.4x priced for continued growth |
| Trailing P/E | 19.2x reasonably valued |
| Revenue growth | 6.0% slow but positive growth |
| Profit margin | 16.0% healthy profit margins |
| Return on equity | 6.6% a modest return on shareholder capital |
| Debt to equity | 0.27 minimal debt — a conservative balance sheet |
| Current ratio | 1.01 adequate liquidity, worth monitoring |
| Beta | 0.28 barely tracks the market's swings |
| Market cap | $103.8B |
| Employees | 74,846 |
The risks · The things to watch: its business and earnings are exposed to France and to currency swings; as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Latest news · what the market is reading on SNY
- › Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances BioPharma Dive · 16d ago
- › 3 High-Yield Dividend Stocks to Buy and Hold Motley Fool · 16d ago
- › Merck Snags A First-Of-Its-Kind Approval, And Shares Jump Investor's Business Daily · 16d ago
- › Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill Barrons.com · 16d ago
- › Kalshi Will Offer Sports-Style Betting on Drug Trial Results Bloomberg · 17d ago
Headlines from third-party outlets, linked for reference — not our reporting, not advice.
Related securities · others in SNY's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
SNY trades on NASDAQ (ADR) (the company is based in France). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (9 analysts) rates it none, with a mean price target of $56. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (9 analysts) rates it none, with a mean price target of $56. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (9 analysts) rates it none, with a mean price target of $56. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (9 analysts) rates it none, with a mean price target of $56. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (9 analysts) rates it none, with a mean price target of $56. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (9 analysts) rates it none, with a mean price target of $56. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (9 analysts) rates it none, with a mean price target of $56.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $42.50 | +2.5% | · | $1,025 | +2.5% |
| 2 months | $44.30 | -1.7% | $2.42 | $1,038 | +3.8% |
| 3 months | $41.34 | +5.4% | $2.42 | $1,113 | +11.3% |
| 6 months | $46.29 | -5.9% | $2.42 | $994 | -0.6% |
| 1 year | $47.26 | -7.8% | $2.42 | $973 | -2.7% |
| 2 years | $44.33 | -1.7% | $4.63 | $1,087 | +8.7% |
| 3 years | $44.60 | -2.3% | $6.67 | $1,127 | +12.7% |
| 5 years | $43.42 | +0.4% | $10.62 | $1,248 | +24.8% |
Historical returns from market close data. Past performance does not guarantee future results.